# Safety and Pharmacokinetics Study of MT-3921 in Spinal Cord Injury

> **NCT04096950** · PHASE1 · COMPLETED · sponsor: **Tanabe Pharma America, Inc.** · enrollment: 3 (actual)

## Conditions studied

- Spinal Cord Injury

## Interventions

- **BIOLOGICAL:** MT-3921 Low dose

## Key facts

- **NCT ID:** NCT04096950
- **Lead sponsor:** Tanabe Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-19
- **Primary completion:** 2021-01-06
- **Final completion:** 2021-01-06
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2023-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04096950

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04096950, "Safety and Pharmacokinetics Study of MT-3921 in Spinal Cord Injury". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04096950. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*